查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2026843

中和抗體市場預測至2034年—按抗體類型、分銷管道、應用、最終用戶和地區分類的全球分析

Neutralizing Antibody Market Forecasts to 2034 - Global Analysis By Antibody Type, Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球中和抗體市場規模將達到 2,575 億美元，並在預測期內以 10.6% 的複合年成長率成長，到 2034 年將達到 5,767 億美元。

免疫系統會產生一種稱為中和抗體的抗體。這些抗體能夠選擇性地靶向細菌和病毒等病原體，並抑制它們的活性。透過與病原體表面的特定位點結合，這些抗體可以阻止病原體感染或損傷宿主細胞。透過抑制病原體進入細胞並在細胞內繁殖，這些抗體有助於免疫系統控制感染疾病並促進癒合。

根據 GLOBOCAN 2020 報告，全球新增癌症病例 1,930 萬例，癌症相關死亡人數約 1,000 萬，癌症病例的增加是該市場的主要成長要素。

感染疾病數量不斷增加

肝炎、愛滋病和呼吸道感染疾病等感染疾病在全球仍十分常見。中和抗體的使用是治療這些疾病的一種很有前景的策略。隨著這些感染疾病的增加，對中和抗體的需求預計將進一步增加。此外，自體免疫疾病盛行率的上升預計也將推動市場擴張。

監管挑戰

新型抗體療法的監管核准需要對其安全性和有效性進行全面評估。監管機構通常要求提供完整的臨床數據，這可能導致研發週期延長和成本增加。對於中和抗體而言尤其如此，因為它們通常具有獨特性和複雜性，這使得企業難以應對法規環境。監管問題可能會嚴重限制市場。

抗體工程和設計方面的進展

抗體工程和設計技術的不斷進步使得生產最佳化的中和抗體成為可能。親和性成熟和抗體人源化是提高抗體安全性、半衰期和療效的兩種常用技術。抗體片段和抗體藥物複合體（ADC）等新型平台的出現，拓展了治療藥物研發的可能性，這也是市場成長的主要驅動力。

高昂的開發和治療成本

中和抗體的製備和生產過程成本高且耗時。高昂的研發成本源自於大量的研發活動、臨床試驗和生產費用。此外，中和抗體療法的費用可能非常昂貴，這會限制患者的可及性，尤其是在預算和資源有限的醫療系統中。

新冠疫情的影響：

中和抗體市場受到新冠肺炎疫情的顯著影響。中和抗體已成為新冠肺炎治療和預防的關鍵手段。多種單株抗體療法已獲核准或授權用於緊急情況。由於對SARS-CoV-2中和抗體的需求激增，該市場實現了顯著成長。

在預測期內，單株抗體細分市場預計將是最大的。

在預測期內，單株抗體細分市場預計將成為最大的細分市場。對含單株抗體產品的需求、製藥和生物技術產業的擴張以及醫療保健產業基礎設施建設的進步，預計將推動單株抗體市場的成長。在新興市場，由於對更先進、更精確的生產系統的需求不斷成長，以及政府對醫療保健基礎設施現代化的大規模投資，醫療保健產業正在快速擴張。

預計在預測期內，研究機構板塊的複合年成長率將最高。

預計在預測期內，研究機構板塊的複合年成長率將最高。這主要是由於預測期內癌症和其他慢性疾病的發生率不斷上升，以及許多機構不斷完善其研究方案並利用獲得的資金開發新技術。研究機構由公共或私人資金資助，致力於研發可用於診斷、治療或監測人類疾病的現有或未來產品。

市佔率最大的地區：

由於北美擁有完善的標準化國家醫療保健體系和許多大型企業，預計在預測期內將佔據最大的市場佔有率。推動市場成長的因素包括：製造業中尖端基因工程技術的應用、先進的醫療保健體系、政府對感染疾病防治的支持，以及與久坐生活方式相關的疾病日益普遍。

複合年成長率最高的地區：

預計亞太地區在預測期內將維持最高的複合年成長率。市場擴張將受到以下因素的驅動：對圖型基因平台的技術需求不斷成長、基因組學領域研發活動的拓展，以及患者對單株抗體（mAb）療法潛在益處的認知不斷提高。研發產業的擴張和單株抗體生產技術的進步也推動了市場成長。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章：全球中和抗體市場：以抗體類型分類

  • 單株抗體
  • 多株抗體
  • 廣譜中和抗體
  • 交叉中和抗體
  • 其他抗體類型

第6章：全球中和抗體市場：以目標病毒分類

  • SARS-CoV-2
  • 流感
  • HIV
  • 伊波拉
  • C型肝炎
  • 茲卡病毒
  • 其他標靶病毒

第7章 全球中和抗體市場：依分銷管道分類

  • 銷售代理
  • 線上零售

第8章：全球中和抗體市場：按應用分類

  • 診斷
  • 治療
  • 研究與開發
  • 其他用途

第9章 全球中和抗體市場：依最終用戶分類

  • 醫院
  • 製藥公司
  • 研究所
  • 其他最終用戶

第10章 全球中和抗體市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第11章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第12章：公司簡介

  • GlaxoSmithKline plc
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Eli Lilly and Company
  • Sanofi SA
  • AstraZeneca PLC
  • Merck & Co.Inc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Moderna, Inc.
  • Johnson & Johnson
  • BioNTech SE
  • CSL Limite
  • Sinovac Biotech Ltd
  • HaemaLogiX Ltd
Product Code: SMRC24617

According to Stratistics MRC, the Global Neutralizing Antibody Market is accounted for $257.5 billion in 2026 and is expected to reach $576.7 billion by 2034 growing at a CAGR of 10.6% during the forecast period. The immune system produces a kind of antibody known as neutralizing antibodies, which are designed to selectively target and inhibit the action of pathogens like bacteria or viruses. These antibodies stop pathogens from infecting or harming host cells by binding to particular areas, frequently on their surface. These antibodies aid the immune system in managing and curing the infection by blocking the pathogen's capacity to enter cells or multiply.

According to the report of GLOBOCAN 2020, there were 19.3 million new cases of cancer and about 10 million deaths due to cancer in the world, and increasing cancer cases are the major growth factor behind the market.

Market Dynamics:

Driver:

Rising numbers of infectious diseases

Infectious disorders including hepatitis, HIV/AIDS, and respiratory infections are still quite common around the world. A promising therapeutic strategy for the management of these illnesses is the use of neutralizing antibodies. Neutralizing antibodies should become more and more in demand as the incidence of these infectious illnesses rises. Furthermore, it is anticipated that the market would rise in response to the rising prevalence of autoimmune illnesses.

Restraint:

Regulatory challenges

Securing regulatory clearance for novel antibody treatments necessitates thorough assessments of their safety and effectiveness. Comprehensive clinical data is frequently required by regulatory bodies, which might result in lengthier development times and higher costs. Companies may find it difficult to navigate the regulatory environment, particularly when it comes to unique or complicated neutralizing antibodies. The market may be severely constrained by regulatory issues.

Opportunity:

Improvements in antibody engineering and design

Neutralizing antibodies that are optimized can be produced thanks to the ongoing advancements in antibody engineering and design approaches. Affinity maturation and antibody humanization are two techniques used to improve the safety, half-life, and effectiveness of antibodies. Adding new platforms to the mix, including antibody fragments and antibody-drug conjugates, increases the potential for developing therapeutics. This is the main factor driving the market's expansion.

Threat:

Expensive development and treatment costs

The process of creating and producing neutralizing antibodies is expensive and time-consuming. High development costs can be attributed to the considerable research and development activities, clinical trials, and manufacturing expenses. Furthermore, neutralizing antibody therapies might be prohibitively expensive, which may restrict accessibility, especially in healthcare systems with tight budgets and resources.

Covid-19 Impact:

The neutralizing antibody market has been significantly influenced by the COVID-19 pandemic. In order to treat and prevent COVID-19, neutralizing antibodies have been essential. Several monoclonal antibody treatments have been approved or authorized for usage in emergency situations. The market has grown significantly as a result of the spike in demand for neutralizing antibodies against SARS-CoV-2.

The monoclonal antibodies segment is expected to be the largest during the forecast period

The monoclonal antibodies segment is expected to be the largest during the forecast period. The need for goods containing monoclonal antibodies, the expansion of the pharmaceutical and biotechnology sectors, and the availability of enhanced infrastructure for the healthcare industry are all anticipated to fuel the growth of the monoclonal antibody market. The healthcare industry is expanding quickly in emerging countries as a result of the rising need for more advanced sophisticated manufacturing systems and large government investments to modernize healthcare infrastructure.

The research institutes segment is expected to have the highest CAGR during the forecast period

The research institutes segment is expected to have the highest CAGR during the forecast period, owing to the increased incidence of cancer and other chronic illnesses within the anticipated time frame, several organizations have enhanced their research protocols and utilized the funds received to create novel technologies. Funded by public or commercial sources, research institutes conduct investigations on current or forthcoming products that have the potential to be utilized for the diagnosis, treatment, or surveillance of any human ailment.

Region with largest share:

North America is projected to hold the largest market share during the forecast period due to the presence of a standard nationwide healthcare system and the existence of significant critical companies. The employment of cutting-edge genetic engineering technology in manufacturing, a sophisticated healthcare system, government support for infection control and management, and a rise in the prevalence of diseases associated with sedentary lifestyles are some of the factors driving the market's growth.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. Factors driving the market expansion include the rise in technical demand for genetic platforms with improved capabilities, the expansion of research and development activities in the field of genomics, and the growing awareness among patients about the potential benefits of monoclonal antibodies (mAb) therapy. The market's growth is also fueled by the expansion of the R&D industry and technical advancements in the manufacturing of monoclonal antibodies.

Key players in the market

Some of the key players in Neutralizing Antibody market include GlaxoSmithKline plc, Novartis AG, Regeneron Pharmaceuticals, Inc., Roche Holding AG, Eli Lilly and Company, Sanofi SA, AstraZeneca PLC, Merck & Co.Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, Moderna, Inc., Johnson & Johnson, BioNTech SE, CSL Limite, Sinovac Biotech Ltd and HaemaLogiX Ltd.

Key Developments:

In February 2022, Eli Lilly and Company announced that United States Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for bebtelovimab, an antibody that demonstrates neutralization against the Omicron variant.

In January 2022, HaemaLogiX Ltd (HaemaLogiX) and Lonza entered into an agreement to manufacture the next clinical batch (cGMP) of HaemaLogiX's lead multiple myeloma drug candidate, KappaMab, a monoclonal antibody that binds to a cell surface target called kappa myeloma antigen (KMA) that is only found on myeloma cancer cells and not on normal plasma cells.

Antibody Types Covered:

  • Monoclonal Antibodies
  • Polyclonal Antibodies
  • Broadly Neutralizing Antibody
  • Cross Neutralizing Antibody
  • Other Antibody Types

Target Viruses Covered:

  • SARS-CoV-2
  • Influenza
  • HIV
  • Ebola
  • Hepatitis C
  • Zika
  • Other Target Viruses

Distribution Channels Covered:

  • Distributors
  • Online Retail

Applications Covered:

  • Diagnostics
  • Therapeutics
  • Research & Development
  • Other Applications

End Users Covered:

  • Hospitals
  • Pharmaceutical Companies
  • Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Neutralizing Antibody Market, By Antibody Type

  • 5.1 Introduction
  • 5.2 Monoclonal Antibodies
  • 5.3 Polyclonal Antibodies
  • 5.4 Broadly Neutralizing Antibody
  • 5.5 Cross Neutralizing Antibody
  • 5.6 Other Antibody Types

6 Global Neutralizing Antibody Market, By Target Virus

  • 6.1 Introduction
  • 6.2 SARS-CoV-2
  • 6.3 Influenza
  • 6.4 HIV
  • 6.5 Ebola
  • 6.6 Hepatitis C
  • 6.7 Zika
  • 6.8 Other Target Viruses

7 Global Neutralizing Antibody Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Distributors
  • 7.3 Online Retail

8 Global Neutralizing Antibody Market, By Application

  • 8.1 Introduction
  • 8.2 Diagnostics
  • 8.3 Therapeutics
  • 8.4 Research & Development
  • 8.5 Other Applications

9 Global Neutralizing Antibody Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Pharmaceutical Companies
  • 9.4 Laboratories
  • 9.5 Other End Users

10 Global Neutralizing Antibody Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 GlaxoSmithKline plc
  • 12.2 Novartis AG
  • 12.3 Regeneron Pharmaceuticals, Inc.
  • 12.4 Roche Holding AG
  • 12.5 Eli Lilly and Company
  • 12.6 Sanofi SA
  • 12.7 AstraZeneca PLC
  • 12.8 Merck & Co.Inc.
  • 12.9 Pfizer Inc.
  • 12.10 Takeda Pharmaceutical Company Limited
  • 12.11 Moderna, Inc.
  • 12.12 Johnson & Johnson
  • 12.13 BioNTech SE
  • 12.14 CSL Limite
  • 12.15 Sinovac Biotech Ltd
  • 12.16 HaemaLogiX Ltd

List of Tables

  • Table 1 Global Neutralizing Antibody Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Neutralizing Antibody Market Outlook, By Antibody Type (2023-2034) ($MN)
  • Table 3 Global Neutralizing Antibody Market Outlook, By Monoclonal Antibodies (2023-2034) ($MN)
  • Table 4 Global Neutralizing Antibody Market Outlook, By Polyclonal Antibodies (2023-2034) ($MN)
  • Table 5 Global Neutralizing Antibody Market Outlook, By Broadly Neutralizing Antibody (2023-2034) ($MN)
  • Table 6 Global Neutralizing Antibody Market Outlook, By Cross Neutralizing Antibody (2023-2034) ($MN)
  • Table 7 Global Neutralizing Antibody Market Outlook, By Other Antibody Types (2023-2034) ($MN)
  • Table 8 Global Neutralizing Antibody Market Outlook, By Target Virus (2023-2034) ($MN)
  • Table 9 Global Neutralizing Antibody Market Outlook, By SARS-CoV-2 (2023-2034) ($MN)
  • Table 10 Global Neutralizing Antibody Market Outlook, By Influenza (2023-2034) ($MN)
  • Table 11 Global Neutralizing Antibody Market Outlook, By HIV (2023-2034) ($MN)
  • Table 12 Global Neutralizing Antibody Market Outlook, By Ebola (2023-2034) ($MN)
  • Table 13 Global Neutralizing Antibody Market Outlook, By Hepatitis C (2023-2034) ($MN)
  • Table 14 Global Neutralizing Antibody Market Outlook, By Zika (2023-2034) ($MN)
  • Table 15 Global Neutralizing Antibody Market Outlook, By Other Target Viruses (2023-2034) ($MN)
  • Table 16 Global Neutralizing Antibody Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 17 Global Neutralizing Antibody Market Outlook, By Distributors (2023-2034) ($MN)
  • Table 18 Global Neutralizing Antibody Market Outlook, By Online Retail (2023-2034) ($MN)
  • Table 19 Global Neutralizing Antibody Market Outlook, By Application (2023-2034) ($MN)
  • Table 20 Global Neutralizing Antibody Market Outlook, By Diagnostics (2023-2034) ($MN)
  • Table 21 Global Neutralizing Antibody Market Outlook, By Therapeutics (2023-2034) ($MN)
  • Table 22 Global Neutralizing Antibody Market Outlook, By Research & Development (2023-2034) ($MN)
  • Table 23 Global Neutralizing Antibody Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 24 Global Neutralizing Antibody Market Outlook, By End User (2023-2034) ($MN)
  • Table 25 Global Neutralizing Antibody Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 26 Global Neutralizing Antibody Market Outlook, By Pharmaceutical Companies (2023-2034) ($MN)
  • Table 27 Global Neutralizing Antibody Market Outlook, By Laboratories (2023-2034) ($MN)
  • Table 28 Global Neutralizing Antibody Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.